Market Cap (In USD)
205.73 Million
Revenue (In USD)
-
Net Income (In USD)
-35.46 Million
Avg. Volume
562.55 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.18-4.44
- PE
- -1.13
- EPS
- -0.62
- Beta Value
- 1.305
- ISIN
- KYG7S53R1049
- CUSIP
- -
- CIK
- 1850270
- Shares
- 292697644.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Bruce Culleton M.D.
- Employee Count
- -
- Website
- https://www.prokidney.com
- Ipo Date
- 2021-06-30
- Details
- ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
More Stocks
-
KCPSUGIND
-
SRXXFSPARX Group Co., Ltd.
SRXXF
-
APLT
-
9525
-
KOVAI
-
FBSEFastbase, Inc.
FBSE
-
300645
-
TMASFTemas Resources Corp.
TMASF